Cargando…
Clinical outcomes of mild to moderate coronavirus disease 2019 patients treated with Regdanvimab in delta-variant outbreak: Retrospective cohort study
Regdanvimab is a novel neutralizing antibody agent used for the treatment of coronavirus disease 2019 (COVID-19). However, the effectiveness of regdanvimab in delta-variant patients has rarely been investigated. We examined the clinical outcomes and adverse events in COVID 19 patients treated with r...
Autores principales: | Noh, Hyeong-Jun, Song, Jin Hwa, Ham, Sin Young, Park, Yeonkyung, Won, Ha-Kyeong, Kim, Soo Jung, Chung, Keun Bum, Kim, Choon Kwan, Ahn, Young Mee, Lee, Byoung-Jun, Kang, Hye-Rin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637437/ https://www.ncbi.nlm.nih.gov/pubmed/37960790 http://dx.doi.org/10.1097/MD.0000000000035987 |
Ejemplares similares
-
Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant
por: Jang, Young Rock, et al.
Publicado: (2023) -
Clinical characteristics and prognostic risk factors of healthcare-associated pneumonia in a Korean tertiary teaching hospital
por: Ahn, June H., et al.
Publicado: (2017) -
Comparisons of Prognosis between Surgically and Clinically Diagnosed Idiopathic Pulmonary Fibrosis Using Gap Model: A Korean National Cohort Study
por: Lee, Sang Hoon, et al.
Publicado: (2016) -
Clinical Effectiveness of Regdanvimab Treatment for Mild-to-Moderate COVID-19: A Retrospective Cohort Study
por: Jang, Young Rock, et al.
Publicado: (2022) -
Coexistence of lung adenocarcinoma and pulmonary tuberculosis within a single lesion: A rare case report
por: Byun, Hong Gwon, et al.
Publicado: (2019)